Norges Bank Caribou Biosciences, Inc. Transaction History

Norges Bank

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Nov 13, 2023	SELL	$4.08 - $8.14 $1.01 Million - $2.01 Million	-246,500 Closed	0 $0
Q2 2023 Aug 14, 2024	BUY	$4.04 - $5.47 $100,192 - $135,656	24,800 New	24,800 $105,000
Q1 2023 May 15, 2024	BUY	$4.3 - $7.78 $355,610 - $643,406	82,700 New	82,700 $439,000
Q4 2022 Feb 14, 2023	BUY	$5.57 - $11.01 $1.2 Million - $2.38 Million	216,300 New	216,300 $1.36 Million
Q3 2022 Nov 13, 2023	BUY	$5.34 - $12.79 $1.32 Million - $3.15 Million	246,500 New	246,500 $2.6 Million

135

52.6M

148K

70.7K

Ticker CRBU
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 60,840,800
Market Cap $98M
Description
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies and solid tumors in the United States and internationally. Its lead product candidates are CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1...

Get notified when there are updates to the investment portfolio of Norges Bank, based on Form 13F filings with the SEC.

Stay updated on Norges Bank with notifications on news.